Dr. Angela DeMichele, MD
Claim this profileAbramson Cancer Center of the University of Pennsylvania
Expert in Breast Cancer
Studies Breast cancer
11 reported clinical trials
20 drugs studied
Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 positive
Stage II
2Breast Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Angela DeMichele, MD is currently running
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Angela DeMichele, MD
Clinical Trial Related8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Angela DeMichele, MD has experience with
- Palbociclib
- Avelumab
- Everolimus
- Hydroxychloroquine
- Bone Marrow Aspirate
- Plasma/Buffy Coat
Breakdown of trials Angela DeMichele, MD has run
Breast Cancer
Breast cancer
Relapse
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Angela DeMichele, MD specialize in?
Angela DeMichele, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved ER positive patients, or patients who are HER2 positive.
Is Angela DeMichele, MD currently recruiting for clinical trials?
Yes, Angela DeMichele, MD is currently recruiting for 4 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Angela DeMichele, MD has studied deeply?
Yes, Angela DeMichele, MD has studied treatments such as Palbociclib, Avelumab, Everolimus.
What is the best way to schedule an appointment with Angela DeMichele, MD?
Apply for one of the trials that Angela DeMichele, MD is conducting.
What is the office address of Angela DeMichele, MD?
The office of Angela DeMichele, MD is located at: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the Abramson Cancer Center of the University of Pennsylvania.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.